Evidence map›Paper›PMID 36575000›Full record

Trial reportJournal of clinical and experimental hematopathology : JCEH2022

A multicenter, phase II study of full-dose THP-COP therapy for elderly patients with newly diagnosed, advanced-stage, aggressive non-Hodgkin lymphoma.

Ken Ohmachi, Michinori Ogura, Yoshitoyo Kagami, Yosuke Imai, Takayuki Hirose, Tomohiro Kinoshita, Hirokazu Nagai, Kazunori Ohnishi, Tomomitsu Hotta

Open access · goldAbstract readClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of clinical and experimental hematopathology : JCEH, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 1 country.

Ken OhmachiDepartment of Hematology and Oncology, Tokai University School of Medicine, Isehara, Japan.
Michinori OguraDepartment of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Nagoya, Japan.
Yoshitoyo KagamiDepartment of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Nagoya, Japan.
Yosuke ImaiDepartment of Internal Medicine, Niigata Cancer Center Hospital, Niigata, Japan.
Takayuki HiroseDepartment of Internal Medicine, Niigata Cancer Center Hospital, Niigata, Japan.
Tomohiro KinoshitaDepartment of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Hirokazu NagaiDepartment of Hematology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Kazunori OhnishiDepartment of Hematology, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Tomomitsu HottaDepartment of Hematology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Aichi Cancer Center · JPNagoya Medical Center · JPNiigata Cancer Center Hospital · JPHamamatsu University School of Medicine · JPNagoya University · JPTokai University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) regimen, containing doxorubicin (DXR), which is a key drug for aggressive non-Hodgkin lymphoma (NHL), is a standard chemotherapeutic regimen; however, its administration in elderly patients is often intolerable. Pirarubicin (tetrahydropyranyl adriamycin [THP]) is an anthracycline developed in Japan. We have conducted a phase II trial of a full-dose THP-COP (modified CHOP regimen with DXR replaced by THP) regimen for elderly patients with newly diagnosed, advanced-stage, aggressive NHL. Patients aged 70-79 years old with previously untreated NHL according to the Working Formulation (D through H and J), disease stage I with a bulky mass or stage II-IV, and performance status of 0-1 were eligible. The THP-COP regimen, which consisted of 750-mg/m

Indexed as

Lymphoma, Non-HodgkinAgedAntineoplastic Combined Chemotherapy ProtocolsCyclophosphamideDoxorubicinHumansPrednisolonePrednisoneTreatment OutcomeVincristineCyclophosphamideDoxorubicinpirarubicinPrednisolonePrednisoneVincristineaggressive non-Hodgkin lymphomaelderly Japanesepirarubicin

Identifiers

PMID36575000
PMCPMC9898716
OpenAlexW4313143758

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.